San Diego-based Halozyme Therapeutics reported today that the firm has named H. Michael Shepard, Ph.D., as the firm's new Vice President of Discovery Research. According to Halozyme, Shepard was most recently at Receptor Biologix, where he was founder and President. He has also served at Canji, and worked at Genentech on that firm's Herceptin compound. Halozyme is developing biopharmaceuticals targeted at the endocrinology, oncology, dermatology and drug delivery markets.
Top NewsWednesday, June 17, 2009
Halozyme Therapeutics Names VP